UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State
or other jurisdiction of
incorporation or organization) |
(Commission File Number) | IRS
Employer Identification No.) |
(Address of principal executive offices)
Registrant’s
telephone number, including area code: (
(Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class: | Trading Symbol(s) | Name of each exchange on which registered: | ||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.07 Submission of Matters to a Vote of Security Holders
On June 20, 2024, Unicycive Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). As of the close of business on April 25, 2024, the record date for the Annual Meeting, the holders of the Company’s capital stock were entitled to an aggregate of 46,140,413 votes, comprised of (i) an aggregate of 37,606,436 votes to which the holders of the Company’s 37,606,436 shares of outstanding common stock were entitled; (ii) 1,586,165 votes to which the holders of the Company’s 19,991.51 shares of outstanding Series A Preferred Stock were entitled; and (iii) 6,947,812 votes to which the holders of the Company’s 50,000 shares of outstanding Series B Preferred Stock were entitled.
An aggregate of 35,912,732 votes were represented in person or by valid proxies at the Annual Meeting, or approximately 78% of the total voting power of the shares of the Company’s capital stock entitled to vote. The final results for each of the matters submitted to a vote of stockholders at the Annual Meeting, as set forth in the Definitive Proxy Statement, filed with the Securities and Exchange Commission on April 26, 2024 are as follows:
Proposal 1. All of the four (4) nominees for director were elected to serve until the 2025 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified, or until such director’s earlier resignation, removal or death. The result of the votes to elect the four (4) directors was as follows:
| Directors | For | Withhold | Broker Non Vote | |||||||||
| Dr. Shalabh Gupta | 31,405,300 | 141,215 | 4,366,217 | |||||||||
| Dr. Sandeep Laumas | 26,680,456 | 4,863,859 | 4,366,417 | |||||||||
| Dr. Gaurav Aggarwal | 31,361,230 | 185,285 | 4,366,217 | |||||||||
| Dr. Saraswati Kenkare-Mitra | 27,910,020 | 3,636,495 | 4,366,217 | |||||||||
Proposal 2. The appointment of Grassi & Co. CPAs, P.C. as the Company’s independent registered public accounting firm for its fiscal year ended December 31, 2024 was ratified and approved by the stockholders by the votes set forth in the table below:
| For | Against | Abstain | Broker Non Vote | |||||||||||
| 35,666,926 | 156,292 | 89,512 | 2 | |||||||||||
Proposal 3. The Nasdaq 20% Issuance Proposal was approved by the stockholders by the votes set forth in the table below:
| For | Against | Abstain | Broker Non Vote | |||||||||||
| 26,794,427 | 262,272 | 9,804 | 4,366,219 | |||||||||||
Proposal 4. The Authorized Share Increase Proposal was approved by the stockholders by the votes set forth in the table below:
| For | Against | Abstain | Broker Non Vote | |||||||||||
| 34,150,333 | 1,735,688 | 26,730 | 1 | |||||||||||
Proposal 5. The second amendment and restatement of the 2021 Omnibus Equity Incentive Plan was approved by the stockholders by the votes set forth in the table below:
| For | Against | Abstain | Broker Non Vote | |||||||||||
| 26,540,959 | 4,988,094 | 17,462 | 4,366,217 | |||||||||||
1
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: June 20, 2024
| UNICYCIVE THERAPEUTICS, INC. | ||
| By: | /s/ Shalabh Gupta | |
| Shalabh Gupta | ||
| Chief Executive Officer | ||
2